Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

298
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
298
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

491
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
491
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

172
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
172
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

29
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Large language models for deductive qualitative content analysis in dementia-focused embedded pragmatic clinical trials: A comparative methodological study.

Implementation science communications·2026
Same author

Ten Questions for Ethics Committees Evaluating the Strength of Evidence in Support of Early Phase Trials.

Ethics & human research·2026
Same author

Challenges of Conducting Risk-Benefit Analysis of Early Phase Clinical Trials: Results of a National Survey of IRB Chairs.

Ethics & human research·2025
Same author

Flying Blind: How Thorough are IRBs when Assessing Scientific Value?

Journal of general internal medicine·2024
Same author

Algorithmic identification of persons with dementia for research recruitment: ethical considerations.

Informatics for health & social care·2024
Same author

Digital Health Technologies in Clinical Trials: An Ontology-Driven Analysis to Inform Digital Sustainability Policies.

Therapeutic innovation & regulatory science·2023

Related Experiment Video

Updated: Feb 22, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.6K

Ethical Challenges in Biomarker-Driven Drug Development.

Spencer Phillips Hey1,2

  • 1Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|September 26, 2017
PubMed
Summary
This summary is machine-generated.

Biomarkers are crucial for research, clinical trials, and precision medicine, presenting new ethical challenges. This review covers existing debates and introduces a novel ethical issue stemming from abstract biomarker hypotheses.

More Related Videos

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.7K

Related Experiment Videos

Last Updated: Feb 22, 2026

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.6K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.3K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.7K

Area of Science:

  • Biomedical Ethics
  • Translational Research
  • Precision Medicine

Background:

  • Biomarkers are increasingly vital in scientific research and drug development.
  • Their roles include serving as surrogate outcomes in clinical trials and enabling precision medicine.
  • This growing importance introduces complex ethical considerations.

Purpose of the Study:

  • To review existing ethical challenges and debates surrounding biomarker research.
  • To introduce and discuss a newly identified ethical challenge.
  • To address the ethical implications arising from the abstract nature of biomarker hypotheses.

Main Methods:

  • Literature review of identified ethical challenges and debates in biomarker research.
  • Conceptual analysis of ethical issues related to biomarker hypotheses.

Main Results:

  • Existing literature highlights several ethical challenges in biomarker research and application.
  • A novel ethical challenge is identified, stemming from the abstract nature of biomarker hypotheses.
  • This abstract nature poses unique ethical dilemmas not yet fully explored.

Conclusions:

  • The expanding role of biomarkers necessitates ongoing ethical scrutiny.
  • New ethical challenges, particularly those related to abstract hypotheses, require further investigation.
  • Addressing these ethical issues is crucial for responsible advancement in biomarker-driven research and medicine.